Glioblastoma Multiforme Clinical Trial
Official title:
Phase I Trial of AZD8055, An Oral MTOR Kinase Inhibitor, for Adults With Recurrent Gliomas
Background:
- AZD8055 is an experimental cancer treatment drug that works by inhibiting a protein called
mTOR, which is known to promote tumor cell and blood vessel growth and to control tumor s
energy and nutrient levels. AZD8055 is the first drug that inhibits both types of mTOR
protein and is expected to be more effective than prior mTOR inhibitors. However, more
research is needed to determine its safety and effectiveness in treating brain tumors known
as gliomas that have not responded to standard treatments.
Objectives:
- To evaluate the safety and effectiveness of AZD8055 in individuals with gliomas that have
not responded to standard treatments.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with gliomas that have not
responded to standard chemotherapy, surgery, or radiation.
Design:
- Participants will be screened with a physical examination, medical history, blood tests,
and tumor imaging studies.
- Participants will be separated into two treatment groups: one group that will receive
surgery to remove the glioma and one that will not have surgical treatment.
- Participants in the nonsurgical treatment group will take AZD8055 by mouth daily for a
42-day cycle of treatment. Participants will keep a diary to record doses and keep track
of any side effects.
- Participants in the surgical treatment group will take AZD8055 by mouth daily for 7
days, and then will have tumor removal surgery. At least 3 weeks after surgery,
participants will resume doses of AZD8055 and will continue to take the drug for as long
as the tumor does not recur.
- During treatment, participants will have regular visits to the clinical center,
involving frequent blood and urine tests and other examinations to monitor the effects
of treatment. Participants will have imaging studies to study the cancer's response to
the treatment.
- Participants will continue to have cycles of treatment for as long as the treatment
continues to be effective and the side effects are not severe enough to stop
participation in the study....
Background:
- Recurrent glioma patients have very limited treatment options. A significant percentage
of gliomas have increased activity of the PI3K/Akt/mTOR pathway, mostly due to loss of
PTEN.
- AZD8055 is a first in-class inhibitor of the kinase activity of mTOR, specifically
inhibiting both mTORC1 and mTORC2 complexes. Preclinical data generated in the
Neuro-Oncology Branch Laboratory of Dr. Howard Fine demonstrated that AZD8055 has
significant anti-glioma activity in vivo and in vitro.
Objectives:
- To establish the maximally tolerated dose (MTD) of continuous once daily AZD8055 in
patients with recurrent malignant gliomas not on enzyme-inducing anti-epileptic drugs
(EIAED).
- To generate pharmacokinetic data on continuous once daily AZD8055 dosing.
Eligibility:
-Patients with histologically proven glioma are eligible for this study. Patients should have
failed prior standard treatment with radiotherapy.
Design:
- This study will accrue up to 24 evaluable patients (non-surgical arm). Cohorts of 3 or 6
patients will receive continuous AZD8055 once daily orally for 42 days. The MTD will be
based on the tolerability observed during the first 6 weeks of treatment only. Up to
three patients may be enrolled simultaneously at each dose level. The dose of AZD8055
can be progressively escalated if only 0/3 or 1/6 patients experience a dose limiting
toxicity at the prior dose level.
- A subset of patients in whom tumor re-resection is considered standard of care will
receive 1-week treatment with AZD8055 and then undergo resection. Patients will be
treated at the highest dose level shown to be safe at the time of enrollment. Once
patients recover from surgery, they will restart treatment with AZD8055 and stay on
treatment as long as there is no tumor progression or protocol-mandated removal
criteria. Management of toxicity will be the same as non-surgical patients receiving
their second and subsequent cycles of therapy as delineated in the protocol. Up to 12
patients will enter the surgical arm of this trial.
- The accrual ceiling will be open to 42 patients to factor in replacing those who come
off
treatment prior to cycle 1.
-At the end of Cycle 1, patients in both treatment arms (surgical and non-surgical) may
choose to continue to receive AZD8055 until disease progression or until they experience
unmanageable drug related toxicity, as long as they are continuing to derive clinical benefit
and do not fulfill any of the criteria for removal from protocol therapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05023551 -
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
|
Early Phase 1 | |
Recruiting |
NCT06059690 -
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116411 -
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
|
Phase 2 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00038493 -
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Recruiting |
NCT01923922 -
CT Perfusion in the Prognostication of Cerebral High Grade Glioma
|
N/A | |
Completed |
NCT01956734 -
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
|
Phase 1 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Completed |
NCT01301430 -
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
|
Phase 1/Phase 2 | |
Completed |
NCT01402063 -
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
|
Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Terminated |
NCT00990496 -
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Recruiting |
NCT05366179 -
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
|
Phase 1 |